Sierra Oncology, Inc. SRRA
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 54.98
- Prev close
- 54.99
- Mkt cap
- 1.34B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 54.98
- High
- 55.01
- Forward P/E
- -14.25
- Beta
- 0.02
- Short ratio
- 2.41
- Inst. own
- 76.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 4, 2022
- 50-d avg
- 54.73
- 200-d avg
- 33.69
- 1y target
- 55.00
News
4 years ago zacks.com
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
4 years ago businesswire.com
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra…
4 years ago businesswire.com
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed…
4 years ago stockmarket.com
Best Biotech Stocks To Buy Now? 5 To Know
Check out these biotech stocks with exciting developments today.
4 years ago prnewswire.com
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or…
4 years ago invezz.com
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of…
4 years ago investorplace.com
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
4 years ago benzinga.com
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash,…
4 years ago schaeffersresearch.com
Sierra Oncology Stock Soars After Buyout
Sierra Oncology Inc (NASDAQ:SRRA) stock is soaring today, up 38% at $54.52, after news that GlaxoSmithKline (GSK) is purchasing the company for $1.9 billion.
4 years ago marketwatch.com
GSK to buy Sierra Oncology for $1.9 billion
Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is…
4 years ago barrons.com
Sierra Oncology Soars After Takeover by Glaxo
The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.
4 years ago fool.com
Why Sierra Oncology Stock Is Soaring Today
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
4 years ago benzinga.com
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion).…
4 years ago pulse2.com
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details.
4 years ago marketwatch.com
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.
-
4 years ago reuters.com
GSK to buy Sierra Oncology for $1.9 billion
Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.
4 years ago businesswire.com
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs.
4 years ago seekingalpha.com
Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
4 years ago businesswire.com
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the…
4 years ago seekingalpha.com
Sierra Oncology: Plenty Of Room To Trade Higher After Latest Myelofibrosis Data
Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of myelofibrosis patients who are symptomatic and anemic. Momelotinib has a competitive advantage…
-
4 years ago benzinga.com
Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Sales Miss Views
Following the market opening Tuesday, the Dow traded down 1.79% to 33,748.82 while the NASDAQ fell 2.56% to 13,499.97. The S&P also fell, dropping, 2.59% to 13,496.29.
-
5 years ago benzinga.com
58 Biggest Movers From Yesterday
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
During Friday's morning trading, 47 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 239 stocks hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Wednesday morning saw 162 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
This morning 279 companies reached new 52-week highs.